Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

BACKGROUND AND OBJECTIVES: Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to evaluate the pharmacokinetic properties of once-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Drug Metab Pharmacokinet
Main Authors: Rubino, Christopher M., Onufrak, Nikolas J., van Ingen, Jakko, Griffith, David E., Bhavnani, Sujata M., Yuen, Dayton W., Mange, Kevin C., Winthrop, Kevin L.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2021
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7935831/
https://ncbi.nlm.nih.gov/pubmed/33595792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13318-020-00669-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados